Range of Factors Will Drive Strong Pharma Deal Flow

In this ISSUE

Gateways to Success in Cell and Gene Therapies

Patient Support Programs: Cost, Benefit, and Resourcing

Patient Input and Patient Preference Studies

Top Story

M&A: Range of Fundamental Factors Will Drive Strong Deal Flow

The outlook for pharma M&A continues to be strong, writes Michael Jewell.
… /Read more/

Patient Adherence: A Hard Pill to Swallow?
Asia-Pacific: Thursday, April 11, 2019 at 11:30am IST | 2pm CST | 3pm JST
North America: Thursday, April 11, 2019 at 1pm EDT | 12pm CDT | 10am PDT

Strategy

The Incentive Compensation Plan Landscape

As pharma companies become increasingly focused on retaining key sales people, they continually consider ways to leverage variable compensation as a strategic tool for maximizing the return on their investment in top talent, writes Partha S. Anbil
… /Read more/

Opinion

Time is Running Out for Pharma to Change Course

Pharma needs to find new sources of revenue that also contribute to improved health outcomes. Outside of raising prices, new revenue can come from just three other sources, writes Tom Kottler
… /Read more/

Using Real-World Evidence for U.S. Regulatory Decision-Making: What Pharma Needs to Know
On Demand

Learn More

Opinion

KOLs: An Endangered Buzzword

KOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures, writes Paul Chew
… /Read More/

Japan Market Entry: How to Navigate the Clinical Development Regulatory Environment and Best Methods to Utilize Opportunities
On Demand

Learn More

Regulatory

Primed for Progress: FDA's Pre-Cert Program for Digital Health Devices

Executives from DIA, Ranjini Prithviraj and Sudip Parikh, discuss documents the FDA released that further detail the agency's implementation plan for its Software Precertification Pilot Program
… /Read More/

Calendar

/ April 16–18, 2019: PCC 2019—CBI's 16^th Annual Pharmaceutical Compliance Congress /

Washington, DC

/ May 15: MDR Workshop: Transitioning to the EU MDR and Managing Legacy Devices /

Brussels, Belgium

/ May 20–22: 21^st Medicaid and Government Pricing Congress /

Orlando, FL

/ June 3–6: BIO International Convention /

Philadelphia, PA

/ June 12–13: Rare Disease Innovation and Partnering Summit /

Boston, MA

Industry update

//Agios Pharmaceuticals (Cambridge, MA) promoted Darrin Miles to Senior Vice President, U.S. commercial and global marketing. // Surface Oncology (Cambridge, MA) announced the appointment of Wendy Dwyer as Chief Business Officer. // Collegium Pharmaceutical (Stoughton, MA) appointed Richard Malamut, M.D., as Chief Medical Officer // Provectus (Knoxville, TN) named Heather Raines as the Chief Financial Officer. // CytomX Therapeutics (South San Francisco, CA) announced that its Chief Financial Officer, Debanjan Ray, will be stepping down, effective May 15, to become CEO of a newly formed private biotechnology company. CytomX is initiating the search for Mr. Ray's successor.

The Pharm Exec Podcast: Digital Medicine

The Pharm Exec editors speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial
… /Click here to listen/

advertise with us / print subscribe / digital subscribe / visit pharmexec.com